*Please scroll down for English news
中国无锡
2021年5月14日
全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）与药明康德子公司合全药业今日宣布正式成立合资公司药明合联（WuXi XDC）。该公司将专注于从事抗体偶联药物（ADCs）等生物偶联药物合同研发生产服务（CDMO），并由李锦才博士出任首席执行官。
根据双方签署的合资协议，药明生物和合全药业将各自出资1.2亿美元和8000万美元，分别持有药明合联的60%和40%股份。药明合联将成为药明生物的非全资子公司，提供从抗体和其他偶联生物药、连接子/有效载荷到生物偶联药物原液及制剂的端到端服务。
“生物偶联药物作为解决未满足医疗需求的后起之秀，近年来迎来了蓬勃发展。我们非常高兴恰逢其时地推出药明合联，强强联合药明生物与合全药业的能力和规模优势，更好地提供一体化研发生产服务，支持全球合作伙伴布局创新生物偶联药物，加速研发进程，降低成本。”药明生物首席执行官、药明合联董事长陈智胜博士表示，“我们也很高兴宣布李锦才博士的新任命，我们相信他的出色领导能力，将助力药明合联建立卓越的生物偶联药物CDMO服务能力，赋能全球合作伙伴实现生物偶联药物从概念到商业化生产的全过程。”
合全药业首席执行官陈民章博士表示：“很多生物偶联创新药研发企业经常需要在抗体、连接子/有效载荷、生物和化学偶联等各个方面与多家CDMO进行合作，从而面临复杂的全球供应链以及项目管理的挑战。在过去几年，我们与药明生物在ADC以及其他各种新型生物偶联药物开发方面密切合作，共同致力于为合作伙伴提供高效研发和生产生物偶联药的一体化服务。随着药明合联的成立，我们将会更好地整合合全药业和药明生物双方在各自领域中业界领先的资源，进一步优化生物偶联药物研发生产的平台能力，支持更多新药更快上市，惠及更多病患。”
药明合联首席执行官李锦才博士表示：“我很荣幸领导药明合联。药明合联将充分利用药明生物与合全药业的领先技术和强劲产能，打造卓越的生物偶联药一体化技术平台，加速赋能全球合作伙伴研发高质量生物偶联药物，造福广大病患。”
李锦才博士于2011年加入药明生物，拥有20年生物制药研发和产业化经验，涵盖工艺研发，放大和临床及商业化GMP生产等领域。在药明生物任职期间，李博士领导组建了细胞培养工艺开发和中试生产等多个重要部门，并在随后管理生物药原液一厂（MFG1）期间带领团队通过了首个美国FDA和欧盟EMA的药品上市批准前检查。在加入药明生物之前，李博士曾在Diversa Corporation（现巴斯夫）、Tanox和基因泰克（Genentech）等出任要职。李博士毕业于清华大学化工系，并获得美国马里兰大学生化工程系博士学位。
关于药明生物
药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
截至2021年3月22日，在药明生物平台上研发的综合项目达361个，包括190个处于临床前研究阶段，137个在临床早期（I期，II期）阶段，32个在后期临床（III期）以及2个在商业化生产阶段。预计到2024年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能将达到43万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并成立了由首席执行官领导的ESG委员会，在提升运营效率的同时践行可持续性发展承诺。如需更多信息，请访问：www.wuxibiologics.com。
关于合全药业
合全药业是在中美两地均有运营的药明康德子公司，服务于生命科学行业，拥有卓越的化学创新药研发和生产的能力和技术平台。作为全球新药合作研究开发生产领域（CDMO）的领军企业，合全药业致力于为全球合作伙伴提供从临床前到商业化，高效、灵活、高质量的一站式CMC（化学、生产和控制）解决方案。更多信息，请访问公司网站：www.STApharma.com.cn。
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
WUXI, China
May 14, 2021
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs). Dr. Jimmy (Jincai) Li was appointed as CEO of WuXi XDC.
Per the terms of the joint venture agreement, WuXi Biologics and WuXi STA will make capital contributions of USD120 million and USD80 million respectively to WuXi XDC. WuXi XDC will be owned by WuXi Biologics for 60% and WuXi STA for 40%. Accordingly, WuXi XDC will become a non-wholly owned subsidiary of WuXi Biologics, providing services for development and manufacturing of antibodies or other biologics, chemical payloads and linkers, and the bioconjugated Drug Substance (DS) and Drug Product (DP).
"Bioconjugates have recently emerged as an exciting therapeutic modality to address unmet medical needs. We're excited about establishing WuXi XDC, a dedicated end-to-end bioconjugate CDMO which will combine the world-class capacities and capabilities of both WuXi Biologics and WuXi STA to provide a superior one-stop service for global partners in an effort to expedite development and lower costs." Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi XDC, commented, "We are also delighted to announce Jimmy's new appointment and are confident that he will lead the company to establish a global outstanding bioconjugate CDMO to enable these novel therapeutics into the clinic and eventually on to commercialization."
Dr. Minzhang Chen, CEO of WuXi STA, commented, "Many ADC drug development companies face complex global supply chain and project management challenges with multiple contract partners to handle antibody, payload, linker and conjugations. In the past years, WuXi STA worked closely with WuXi Biologics on ADC therapeutics as well as other novel bioconjugates to provide our customers an expedited development pathway. Now with the initiative of WuXi XDC, we will further combine industry leading resources from both WuXi STA and WuXi Biologics, empowering more partners with a further optimized bioconjugates development and manufacture platform to launch their novel therapeutics faster to market for the benefit of global patients."
Dr. Jimmy Li, newly appointed CEO of WuXi XDC, commented, "I am very honored for the opportunity to lead WuXi XDC. By leveraging both the robust capacities and state-of-the-art technologies of WuXi Biologics and WuXi STA, WuXi XDC will further increase its unique presence in the bioconjugates industry to enable global partners as they build their innovative ideas into transformative new treatments for patients worldwide."
Dr. Jimmy Li has been with WuXi Biologics since 2011. In the nearly 10 years with WuXi Biologics, Dr. Li led various functions, including the establishment of Cell Culture Process Development and Pilot Plant Production group, followed by management of the MFG1 facility, where the first commercial biologics manufactured by WuXi Biologics was approved by the U.S. FDA and EMA. Dr. Jimmy Li has 20 years' experience in biologics process development, scale-up and cGMP manufacturing at Diversa Corporation (now BASF), Tanox and Genentech. Dr. Li holds B.S. degree from Tsinghua University, and Ph.D. degree from University of Maryland Baltimore County, majoring in Chemical and Biochemical Engineering.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients.
As of March 22, 2021, there were a total of 361 integrated projects, including 190 projects in pre-clinical development stage, 137 projects in early-phase (phase I and II) clinical development, 32 projects in late-phase (phase III) development and 2 projects in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore around 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
WuXi Biologics views Environmental, Social, and Governance (ESG) as an integral component of its ethos and business strategy and has established an ESG committee led by the CEO to increase the efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit www.wuxibiologics.com.
About WuXi STA
WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) solutions from preclinical to commercial uses. For more information, please visit: http://www.STApharma.com and follow us on LinkedIn.
媒体联系 PR@wuxibiologics.com
投资者联系 IR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
